Enorama Pharma (Sweden) Performance
| ERMA Stock | SEK 0.65 0.08 10.96% |
The firm shows a Beta (market volatility) of 3.21, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enorama Pharma will likely underperform. At this point, Enorama Pharma AB has a negative expected return of -0.95%. Please make sure to confirm Enorama Pharma's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Enorama Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | -1.8 M |
Enorama |
Enorama Pharma Relative Risk vs. Return Landscape
If you would invest 248.00 in Enorama Pharma AB on December 5, 2025 and sell it today you would lose (183.00) from holding Enorama Pharma AB or give up 73.79% of portfolio value over 90 days. Enorama Pharma AB is generating negative expected returns and assumes 16.7888% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Enorama on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Enorama Pharma Target Price Odds to finish over Current Price
The tendency of Enorama Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.65 | 90 days | 0.65 | under 95 |
Based on a normal probability distribution, the odds of Enorama Pharma to move above the current price in 90 days from now is under 95 (This Enorama Pharma AB probability density function shows the probability of Enorama Stock to fall within a particular range of prices over 90 days) .
Enorama Pharma Price Density |
| Price |
Predictive Modules for Enorama Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enorama Pharma AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Enorama Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Enorama Pharma is not an exception. The market had few large corrections towards the Enorama Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enorama Pharma AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enorama Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.02 | |
β | Beta against Dow Jones | 3.21 | |
σ | Overall volatility | 0.62 | |
Ir | Information ratio | -0.06 |
Enorama Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enorama Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enorama Pharma AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Enorama Pharma AB generated a negative expected return over the last 90 days | |
| Enorama Pharma AB has high historical volatility and very poor performance | |
| Enorama Pharma AB has some characteristics of a very speculative penny stock | |
| Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M. | |
| Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 78.0% of Enorama Pharma shares are held by company insiders |
Enorama Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enorama Stock often depends not only on the future outlook of the current and potential Enorama Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enorama Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.7 M | |
| Cash And Short Term Investments | 12.2 M |
Enorama Pharma Fundamentals Growth
Enorama Stock prices reflect investors' perceptions of the future prospects and financial health of Enorama Pharma, and Enorama Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enorama Stock performance.
| Return On Equity | -32.88 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 42.1 M | |||
| Shares Outstanding | 10.69 M | |||
| Price To Book | 7.67 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 11.04 M | |||
| EBITDA | (25.56 M) | |||
| Cash And Equivalents | 2.01 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 1.7 M | |||
| Debt To Equity | 6.00 % | |||
| Book Value Per Share | (1.22) X | |||
| Cash Flow From Operations | (30.16 M) | |||
| Earnings Per Share | (4.92) X | |||
| Total Asset | 50.93 M | |||
About Enorama Pharma Performance
Assessing Enorama Pharma's fundamental ratios provides investors with valuable insights into Enorama Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Enorama Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about Enorama Pharma AB performance evaluation
Checking the ongoing alerts about Enorama Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enorama Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enorama Pharma AB generated a negative expected return over the last 90 days | |
| Enorama Pharma AB has high historical volatility and very poor performance | |
| Enorama Pharma AB has some characteristics of a very speculative penny stock | |
| Enorama Pharma AB has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 6.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enorama Pharma AB has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Enorama Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Enorama Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enorama Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enorama to invest in growth at high rates of return. When we think about Enorama Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 11.04 M. Net Loss for the year was (27.74 M) with profit before overhead, payroll, taxes, and interest of 3.9 M. | |
| Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 78.0% of Enorama Pharma shares are held by company insiders |
- Analyzing Enorama Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enorama Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Enorama Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enorama Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enorama Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enorama Pharma's stock. These opinions can provide insight into Enorama Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.